<DOC>
	<DOCNO>NCT02039986</DOCNO>
	<brief_summary>This study aim well understanding impact ivacaftor upon insulin incretin secretion glucose tolerance patient Cystic Fibrosis glycine ( G551D ) mutation . Investigators hypothesize treatment ivacaftor improve insulin secretion individual CF .</brief_summary>
	<brief_title>Ivacaftor ( Kalydeco ) Insulin Cystic Fibrosis ( CF )</brief_title>
	<detailed_description>Cystic Fibrosis Related Diabetes ( CFRD ) associate bad nutritional status , great pulmonary function decline , increased mortality , highlight relevance Cystic Fibrosis ( CF ) . CFRD arise primarily compromise insulin secretion - traditionally consider by-product pancreatic exocrine tissue damage fibrosis . Recent development field diabetes propel re-examination basic explanation . The impact cystic fibrosis transmembrane conductance regulator ( CFTR ) potentiator , ivacaftor , upon insulin secretion glucose regulation examine , improve glucose tolerance appreciate anecdotally . This study aim understand impact ivacaftor therapy upon blood glucose insulin incretin secretion .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>6 yrs old cystic fibrosis least one G551D CFTR mutation nonG551D gate mutation , residual function CFTR mutation , limited , R117H mutation , ivacaftor initiate . Plan initiate ivacaftor treatment FDA approve indication clinical care team part ongoing study ivacaftor CFTR mutation , include gate mutation , residual function mutation . pregnant establish diagnosis nonCF relate diabetes ( ie. , Type I diabetes ) history clinically symptomatic pancreatitis past year prior lung liver transplant severe CF liver disease fundoplicationrelated dump syndrome medical comorbidities CFrelated unstable per Investigator opinion acute CF pulmonary exacerbation within 4 week prior study procedure treatment oral intravenous corticosteroid within 4 week study hemoglobin &lt; 10g/dL within 90 day GPA test Screening abnormal renal function within 90 day GPA test Screening longstanding CFRD fasting hyperglycemia , elevate HbA1C ( &gt; 8 ) beyond time surround diagnosis CFRD , significant basal insulin requirement inability perform study specific procedure ( MMTT , GPA ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>CF</keyword>
	<keyword>cystic fibrosis relate diabetes</keyword>
	<keyword>CFRD</keyword>
	<keyword>kalydeco</keyword>
	<keyword>ivacaftor</keyword>
</DOC>